488 related articles for article (PubMed ID: 29287930)
1. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
2. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
[TBL] [Abstract][Full Text] [Related]
3. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
Cherniakov I; Izgelov D; Domb AJ; Hoffman A
Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Atsmon J; Heffetz D; Deutsch L; Deutsch F; Sacks H
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):751-758. PubMed ID: 29125702
[TBL] [Abstract][Full Text] [Related]
5. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
8. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Lee D; Karschner EL; Milman G; Barnes AJ; Goodwin RS; Huestis MA
Drug Alcohol Depend; 2013 Jun; 130(1-3):68-76. PubMed ID: 23146820
[TBL] [Abstract][Full Text] [Related]
9. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb
Knaub K; Sartorius T; Dharsono T; Wacker R; Wilhelm M; Schön C
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426272
[TBL] [Abstract][Full Text] [Related]
10. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
11. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
Varadi G; Zhu Z; Crowley HD; Moulin M; Dey R; Lewis ED; Evans M
Adv Ther; 2023 Jan; 40(1):282-293. PubMed ID: 36308640
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
13. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
14. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
16. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic use of cannabinoids: Forensic aspects.
Indorato F; Liberto A; Ledda C; Romano G; Barbera N
Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
[TBL] [Abstract][Full Text] [Related]
18. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Montero-Escribano P; Vila Silván C
Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.
Izgelov D; Davidson E; Barasch D; Regev A; Domb AJ; Hoffman A
Eur J Pharm Biopharm; 2020 Sep; 154():108-115. PubMed ID: 32634571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
